| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | - | 0 | - | - |
| Research and development | 608 | 496 | 493 | 14 |
| General and administrative | 827 | 960 | 773 | 369 |
| Total operating expenses | 1,435 | 1,456 | 1,266 | 383 |
| Loss from operations | -1,435 | -1,456 | -1,266 | -383 |
| Other nonoperating expense | - | - | - | 537 |
| Interest income | 37 | 34 | 4 | - |
| Interest expense | - | 0 | - | 12 |
| Debt discount amortization | - | 0 | - | 115 |
| Total other income (expenses) | 37 | 34 | 4 | -664 |
| Net loss | -1,398 | -1,422 | -1,262 | -1,047 |
| Basic | 20,206,033 | 17,213,017 | 15,875,485 | 10,910,227 |
| Basic loss per common share | -0.07 | -0.08 | -0.08 | -0.1 |
| Diluted | 20,206,033 | 17,213,017 | 15,875,485 | 10,910,227 |
| Diluted loss per common share | -0.07 | -0.08 | -0.08 | -0.1 |
Kairos Pharma, LTD. (KAPA)
Kairos Pharma, LTD. (KAPA)